{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:56:40Z","timestamp":1793131000572,"version":"4.5.0"},"reference-count":134,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Defense CDMRP","award":["HT9425-24-1-0930"],"award-info":[{"award-number":["HT9425-24-1-0930"]}]},{"name":"Richard Allen Johnson, MD Endowed Chair in Dermatology","award":["HT9425-24-1-0930"],"award-info":[{"award-number":["HT9425-24-1-0930"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Acral melanoma is a distinct subtype of cutaneous malignant melanoma that uniquely occurs on ultraviolet (UV)-shielded, glabrous skin of the palms, soles, and nail beds. While acral melanoma only accounts for 2\u20133% of all melanomas, it represents the most common subtype among darker-skinned, non-Caucasian individuals. Unlike other cutaneous melanomas, acral melanoma does not arise from UV radiation exposure and is accordingly associated with a relatively low tumor mutational burden. Recent advances in genomic, transcriptomic, and epigenomic sequencing have revealed genetic alterations unique to acral melanoma, including novel driver genes, high copy number variations, and complex chromosomal rearrangements. This review synthesizes the current knowledge on the clinical features, epidemiology, and treatment approaches for acral melanoma, with a focus on the genetic pathogenesis that gives rise to its unique tumor landscape. These findings highlight a need to deepen our genetic and molecular understanding to better target this challenging subtype of melanoma.<\/jats:p>","DOI":"10.3390\/biom15010120","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:13:07Z","timestamp":1736835187000},"page":"120","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Acral Melanoma: A Review of Its Pathogenesis, Progression, and Management"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-6988","authenticated-orcid":false,"given":"Soo Hyun","family":"Kim","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hensin","family":"Tsao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semcancer.2019.10.017","article-title":"Translational Pathology, Genomics and the Development of Systemic Therapies for Acral Melanoma","volume":"61","author":"Chen","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/pcmr.12885","article-title":"Acral Lentiginous Melanoma: Basic Facts, Biological Characteristics and Research Perspectives of an Understudied Disease","volume":"34","author":"Adams","year":"2021","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/cancers2020642","article-title":"Acral Lentiginous Melanoma in Situ: A Diagnostic and Management Challenge","volume":"2","author":"Park","year":"2010","journal-title":"Cancers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archderm.1980.01640310043015","article-title":"Acral Lentiginous Melanoma","volume":"116","author":"Coleman","year":"1980","journal-title":"Arch. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jid.2017.08.022","article-title":"Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure","volume":"138","author":"Haugh","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lv, J., Dai, B., Kong, Y., Shen, X., and Kong, J. (2016). Acral Melanoma in Chinese: A Clinicopathological and Prognostic Study of 142 Cases. Sci. Rep., 6.","DOI":"10.1038\/srep31432"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Druskovich, C., Kelley, J., Aubrey, J., Palladino, L., and Wright, G.P. (2024). A Review of Melanoma Subtypes: Genetic and Treatment Considerations. J. Surg. Oncol.","DOI":"10.1002\/jso.27953"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jss.2020.02.010","article-title":"Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006\u20132015, an Analysis of the SEER Registry","volume":"251","author":"Huang","year":"2020","journal-title":"J. Surg. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamadermatol.2013.5941","article-title":"Acral Melanoma: A Unique Disease in Asia","volume":"149","author":"Chang","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dugan, M.M., Perez, M.C., Karapetyan, L., and Zager, J.S. (2024). Management of Acral Lentiginous Melanoma: Current Updates and Future Directions. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1323933"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjd.15600","article-title":"Prognostic Factors and Survival in Acral Lentiginous Melanoma","volume":"177","author":"Asgari","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41568-022-00443-8","article-title":"Un-Fair Skin: Racial Disparities in Acral Melanoma Research","volume":"22","author":"Alicea","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2019.07.008","article-title":"Clinical and Genetic Analysis of Melanomas Arising in Acral Sites","volume":"119","author":"Zaremba","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdin.2020.07.004","article-title":"The Tumor Genetics of Acral Melanoma: What Should a Dermatologist Know?","volume":"1","author":"Tod","year":"2020","journal-title":"JAAD Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct Sets of Genetic Alterations in Melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41467-022-28566-4","article-title":"Integrative Molecular and Clinical Profiling of Acral Melanoma Links Focal Amplification of 22q11.21 to Metastasis","volume":"13","author":"Farshidfar","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1158\/2159-8290.CD-22-0603","article-title":"Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes","volume":"12","author":"Newell","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/labinvest.2016.143","article-title":"Unexpected UVR and Non-UVR Mutation Burden in Some Acral and Cutaneous Melanomas","volume":"97","author":"Rawson","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","article-title":"Whole-Genome Sequencing of Acral Melanoma Reveals Genomic Complexity and Diversity","volume":"11","author":"Newell","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/pcmr.13034","article-title":"Systematic Review and Meta-analysis of Genomic Alterations in Acral Melanoma","volume":"35","author":"Broit","year":"2022","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1101\/gr.213348.116","article-title":"Integrated Genomic Analyses Reveal Frequent TERT Aberrations in Acral Melanoma","volume":"27","author":"Liang","year":"2017","journal-title":"Genome Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-Genome Landscapes of Major Melanoma Subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS Mutant Melanoma: Biological Behavior and Future Strategies for Therapeutic Management","volume":"32","author":"Fedorenko","year":"2012","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","article-title":"The NF1 Gene in Tumor Syndromes and Melanoma","volume":"97","author":"Kiuru","year":"2017","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma Subtypes: Genomic Profiles, Prognostic Molecular Markers and Therapeutic Possibilities","volume":"247","author":"Rabbie","year":"2019","journal-title":"J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.18632\/oncotarget.1892","article-title":"Pathways and Therapeutic Targets in Melanoma","volume":"5","author":"Shtivelman","year":"2014","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1523-1747.1998.00272.x","article-title":"The SCF\/KIT Pathway Plays a Critical Role in the Control of Normal Human Melanocyte Homeostasis","volume":"111","author":"Grichnik","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and Melanoma: Biological Insights and Clinical Implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","article-title":"C-Kit Inhibitors for Unresectable or Metastatic Mucosal, Acral or Chronically Sun-Damaged Melanoma: A Systematic Review and One-Arm Meta-Analysis","volume":"157","author":"Steeb","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/jid.2009.334","article-title":"KIT as a Therapeutic Target in Melanoma","volume":"130","author":"Garrido","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic Activation of KIT in Distinct Subtypes of Melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":"Correlation between KIT Expression and KIT Mutation in Melanoma: A Study of 173 Cases with Emphasis on the Acral-Lentiginous\/Mucosal Type","volume":"22","author":"Wang","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Woodman, S.E., and Davies, M.A. (2010). Targeting KIT in Melanoma: A Paradigm of Molecular Medicine and Targeted Therapeutics. Biochem. Pharmacol., 80.","DOI":"10.1016\/j.bcp.2010.04.032"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0463.2011.02737.x","article-title":"KIT Amplification and Gene Mutations in Acral\/Mucosal Melanoma in Korea","volume":"119","author":"Yun","year":"2011","journal-title":"APMIS"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT Gene Mutations and Copy Number in Melanoma Subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ijc.24048","article-title":"Pathological Activation of KIT in Metastatic Tumors of Acral and Mucosal Melanomas","volume":"124","author":"Ashida","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.jid.5700125","article-title":"Distinctive Role of the cKit Receptor Tyrosine Kinase Signaling in Mammalian Melanocytes","volume":"126","author":"Alexeev","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/labinvest.2016.147","article-title":"Malignant Melanoma of Sun-Protected Sites: A Review of Clinical, Histological, and Molecular Features","volume":"97","author":"Merkel","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45916","DOI":"10.18632\/oncotarget.10001","article-title":"Pharmacological Inhibitors of C-KIT Block Mutant c-KIT Mediated Migration of Melanocytes and Melanoma Cells in Vitro and in Vivo","volume":"7","author":"Posch","year":"2016","journal-title":"Oncotarget"},{"key":"ref_42","first-page":"1968","article-title":"Gene Amplifications Characterize Acral Melanoma and Permit the Detection of Occult Tumor Cells in the Surrounding Skin","volume":"60","author":"Bastian","year":"2000","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/pcmr.12279","article-title":"The Mutational Burden of Acral Melanoma Revealed by Whole-Genome Sequencing and Comparative Analysis","volume":"27","author":"Furney","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13073-022-01068-0","article-title":"Integrated Genomic Analyses of Acral and Mucosal Melanomas Nominate Novel Driver Genes","volume":"14","author":"Wang","year":"2022","journal-title":"Genome Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Garutti, M., Targato, G., Buriolla, S., Palmero, L., Minisini, A.M., and Puglisi, F. (2021). CDK4\/6 Inhibitors in Melanoma: A Comprehensive Review. Cells, 10.","DOI":"10.3390\/cells10061334"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/cdd.2009.68","article-title":"Mdm2-Mediated Ubiquitylation: P53 and Beyond","volume":"17","author":"Marine","year":"2010","journal-title":"Cell Death Differ."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"McConnell, B.B., Gregory, F.J., Stott, F.J., Hara, E., and Peters, G. (1999). Induced Expression of p16INK4a Inhibits Both CDK4- and CDK2-Associated Kinase Activity by Reassortment of Cyclin-CDK-Inhibitor Complexes. Mol. Cell. Biol., 19.","DOI":"10.1128\/MCB.19.3.1981"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/jnci\/djz005","article-title":"Targeted Genomic Profiling of Acral Melanoma","volume":"111","author":"Yeh","year":"2019","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1158\/1078-0432.CCR-17-0070","article-title":"Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4\/6 Inhibitors in Targeted Therapy","volume":"23","author":"Kong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1349-7006.2008.00815.x","article-title":"Increased Copy Number of the TERT and TERC Telomerase Subunit Genes in Cancer Cells","volume":"99","author":"Cao","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT Promoter Mutations in Familial and Sporadic Melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly Recurrent TERT Promoter Mutations in Human Melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6300329","DOI":"10.1155\/2022\/6300329","article-title":"TERT Promoter Mutations and Telomerase in Melanoma","volume":"2022","author":"Guo","year":"2022","journal-title":"J. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/CMR.0000000000000222","article-title":"Molecular Profiling, Including TERT Promoter Mutations, of Acral Lentiginous Melanomas","volume":"26","author":"Vicente","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1038\/s41467-024-50233-z","article-title":"The Genetic Evolution of Acral Melanoma","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Elefanti, L., Zamuner, C., Del Fiore, P., Stagni, C., Pellegrini, S., Dall\u2019Olmo, L., Fabozzi, A., Senetta, R., Ribero, S., and Salmaso, R. (2021). The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083826"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Forschner, A., Hilke, F.-J., Bonzheim, I., Gschwind, A., Demidov, G., Amaral, T., Ossowski, S., Riess, O., Schroeder, C., and Martus, P. (2020). MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12030540"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative Genomic Analyses Identify MITF as a Lineage Survival Oncogene Amplified in Malignant Melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00018-014-1791-0","article-title":"MITF in Melanoma: Mechanisms behind Its Expression and Activity","volume":"72","author":"Hartman","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.1038\/s41467-023-43980-y","article-title":"Delineating the Early Dissemination Mechanisms of Acral Melanoma by Integrating Single-Cell and Spatial Transcriptomic Analyses","volume":"14","author":"Wei","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.18425","article-title":"Genetic Alterations in Primary Melanoma in Taiwan","volume":"182","author":"Sheen","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.7150\/jca.24013","article-title":"Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-Dose Interferon Therapy in Acral Melanoma","volume":"9","author":"Yan","year":"2018","journal-title":"J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.2147\/OTT.S158239","article-title":"TERT Copy Gain Predicts the Outcome of High-Dose Interferon \u03b1-2b Therapy in Acral Melanoma","volume":"11","author":"Yu","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41586-022-04584-6","article-title":"Anatomic Position Determines Oncogenic Specificity in Melanoma","volume":"604","author":"Weiss","year":"2022","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1056\/NEJMc1512354","article-title":"Melanomas and Mechanical Stress Points on the Plantar Surface of the Foot","volume":"374","author":"Minagawa","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMc1706162","article-title":"Acral Melanoma and Mechanical Stress on the Plantar Surface of the Foot","volume":"377","author":"Costello","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1757-1146-6-42","article-title":"Hallux Valgus and Plantar Pressure Loading: The Framingham Foot Study","volume":"6","author":"Galica","year":"2013","journal-title":"J. Foot Ankle Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jbiomech.2011.11.004","article-title":"Spatial Relationships between Shearing Stresses and Pressure on the Plantar Skin Surface during Gait","volume":"45","author":"Stucke","year":"2012","journal-title":"J. Biomech."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5021\/ad.2021.33.1.18","article-title":"PTEN Promoter Hypermethylation Is Associated with Breslow Thickness in Acral Melanoma on the Heel, Forefoot, and Hallux","volume":"33","author":"Park","year":"2020","journal-title":"Ann. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jid.2016.01.024","article-title":"Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival","volume":"136","author":"Roh","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-022-29925-x","article-title":"Weight-Bearing Activity Impairs Nuclear Membrane and Genome Integrity via YAP Activation in Plantar Melanoma","volume":"13","author":"Seo","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature14493","article-title":"Chromothripsis from DNA Damage in Micronuclei","volume":"522","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-Cancer Analysis of Whole Genomes","volume":"578","author":"Aaltonen","year":"2020","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e50292","DOI":"10.7554\/eLife.50292","article-title":"Micronuclei-Based Model System Reveals Functional Consequences of Chromothripsis in Human Cells","volume":"8","author":"Kneissig","year":"2019","journal-title":"eLife"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/s41467-021-21933-7","article-title":"Structural Variant Evolution after Telomere Crisis","volume":"12","author":"Dewhurst","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.4161\/cc.25266","article-title":"Chromothripsis: Breakage-Fusion-Bridge over and over Again","volume":"12","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cell.2013.06.007","article-title":"Catastrophic Nuclear Envelope Collapse in Cancer Cell Micronuclei","volume":"154","author":"Hatch","year":"2013","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-018-0534-z","article-title":"Nuclear Envelope Assembly Defects Link Mitotic Errors to Chromothripsis","volume":"561","author":"Liu","year":"2018","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.cell.2015.06.005","article-title":"Linking Micronuclei to Chromosome Fragmentation","volume":"161","author":"Hatch","year":"2015","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ceb.2021.01.004","article-title":"Causes and Consequences of Micronuclei","volume":"70","author":"Krupina","year":"2021","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41467-020-16134-7","article-title":"The Landscape of Chromothripsis across Adult Cancer Types","volume":"11","author":"Voronina","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in Mechanotransduction","volume":"474","author":"Dupont","year":"2011","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ncb2756","article-title":"Mechano-Transduction and YAP-Dependent Matrix Remodelling Is Required for the Generation and Maintenance of Cancer Associated Fibroblasts","volume":"15","author":"Calvo","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"YAP\/TAZ at the Roots of Cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"109864","DOI":"10.1016\/j.isci.2024.109864","article-title":"The Role of Yes Activated Protein (YAP) in Melanoma Metastasis","volume":"27","author":"Leask","year":"2024","journal-title":"iScience"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1038\/s41388-020-1362-9","article-title":"The Hippo Pathway Oncoprotein YAP Promotes Melanoma Cell Invasion and Spontaneous Metastasis","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Huang, Y., Su, J., Liu, J., Yi, X., Zhou, F., Zhang, J., Wang, J., Meng, X., Si, L., and Wu, C. (2022). YAP Activation in Promoting Negative Durotaxis and Acral Melanoma Progression. Cells, 11.","DOI":"10.2139\/ssrn.4062762"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cell.2020.08.006","article-title":"Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs","volume":"183","author":"Hadi","year":"2020","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/1346-8138.12923","article-title":"Effects of Non-Amputative Wide Local Excision on the Local Control and Prognosis of in Situ and Invasive Subungual Melanoma","volume":"42","author":"Nakamura","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/DSS.0000000000003840","article-title":"Mohs Micrographic Surgery Is Equivalent to Nail Unit Excision or Amputation for Melanoma In Situ of the Nail Unit: A Systematic Review and Meta-Analysis","volume":"49","author":"Le","year":"2023","journal-title":"Dermatol. Surg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1111\/jdv.15742","article-title":"Acral Lentiginous Melanoma and Mucosal Melanoma Expressed Less Programmed-Death 1 Ligand than Cutaneous Melanoma: A Retrospective Study of 73 Japanese Melanoma Patients","volume":"33","author":"Nakamura","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/bjd.17434","article-title":"Efficacy of Nivolumab Monotherapy against Acral Lentiginous Melanoma and Mucosal Melanoma in Asian Patients","volume":"180","author":"Maeda","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100947","DOI":"10.1016\/j.neo.2023.100947","article-title":"Acral Melanoma: New Insights into the Immune and Genomic Landscape","volume":"46","author":"Carvalho","year":"2023","journal-title":"Neoplasia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-21-3145","article-title":"Single-Cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy","volume":"28","author":"Li","year":"2022","journal-title":"Clin. J. Am. Assoc. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1038\/s41467-022-34877-3","article-title":"A Single-Cell Analysis Reveals Tumor Heterogeneity and Immune Environment of Acral Melanoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Si, L., Zhang, X., Shu, Y., Pan, H., Wu, D., Liu, J., Mao, L., Wang, X., Wen, X., and Gu, Y. (2022). Pembrolizumab in Chinese Patients with Advanced Melanoma: 3-Year Follow-up of the KEYNOTE-151 Study. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.882471"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","article-title":"Anti-PD1 Checkpoint Inhibitor Therapy in Acral Melanoma: A Multicenter Study of 193 Japanese Patients","volume":"31","author":"Nakamura","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients with Advanced or Metastatic Melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00262-017-1989-8","article-title":"The Experience of Immune Checkpoint Inhibitors in Chinese Patients with Metastatic Melanoma: A Retrospective Case Series","volume":"66","author":"Wen","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","article-title":"Safety and Efficacy of Nivolumab in Patients with Rare Melanoma Subtypes Who Progressed on or after Ipilimumab Treatment: A Single-Arm, Open-Label, Phase II Study (CheckMate 172)","volume":"119","author":"Nathan","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2022.08.030","article-title":"Efficacy Comparison between Anti-PD-1 Antibody Monotherapy and Anti-PD-1 plus Anti-CTLA-4 Combination Therapy as First-Line Immunotherapy for Advanced Acral Melanoma: A Retrospective, Multicenter Study of 254 Japanese Patients","volume":"176","author":"Nakamura","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e004668","DOI":"10.1136\/jitc-2022-004668","article-title":"Efficacy of Anti-PD-1 and Ipilimumab Alone or in Combination in Acral Melanoma","volume":"10","author":"Bhave","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1200\/JCO.24.01125","article-title":"First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data","volume":"42","author":"Long","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e15067","DOI":"10.1111\/dth.15067","article-title":"Adjuvant PD-1 Inhibitor versus High-Dose Interferon \u03b1-2b for Chinese Patients with Cutaneous and Acral Melanoma: A Retrospective Cohort Analysis","volume":"34","author":"Li","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Muto, Y., Kambayashi, Y., Kato, H., Mizuhashi, S., Ito, T., Maekawa, T., Ishizuki, S., Uchi, H., Matsushita, S., and Yamamoto, Y. (2024). Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma Including Acral and Mucosal Subtypes. Cancers, 16.","DOI":"10.20944\/preprints202407.0117.v1"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/ijc.35060","article-title":"Adjuvant Treatment with Anti-PD-1 in Acral Melanoma: A Nationwide Study","volume":"155","author":"Bloem","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"15945","DOI":"10.1002\/cam4.6234","article-title":"A Real-world Study of Adjuvant anti-PD -1 Immunotherapy on Stage III Melanoma with BRAF, NRAS, and KIT Mutations","volume":"12","author":"Sun","year":"2023","journal-title":"Cancer Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41392-024-02029-2","article-title":"Neoadjuvant Oncolytic Virus Orienx010 and Toripalimab in Resectable Acral Melanoma: A Phase Ib Trial","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41416-022-01942-z","article-title":"Clinical and Genomic Correlates of Imatinib Response in Melanomas with KIT Alterations","volume":"127","author":"Jung","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3727\/096504018X15331163433914","article-title":"Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence from a Retrospective Study","volume":"27","author":"Wei","year":"2019","journal-title":"Oncol. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1158\/1535-7163.MCT-09-1181","article-title":"Preclinical Evaluation of Nilotinib Efficacy in an Imatinib-Resistant KIT-Driven Tumor Model","volume":"9","author":"Cullinane","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"101435","DOI":"10.1016\/j.xcrm.2024.101435","article-title":"Nilotinib in KIT-Driven Advanced Melanoma: Results from the Phase II Single-Arm NICAM Trial","volume":"5","author":"Larkin","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A Phase II Trial of Dasatinib in Patients with Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/cncr.25766","article-title":"A Phase II Trial of Dasatinib in Advanced Melanoma","volume":"117","author":"Kluger","year":"2011","journal-title":"Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","article-title":"Sunitinib Therapy for Melanoma Patients with KIT Mutations","volume":"18","author":"Minor","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1002\/cncr.29622","article-title":"Phase 2 Study of Sunitinib in Patients with Metastatic Mucosal or Acral Melanoma","volume":"121","author":"Buchbinder","year":"2015","journal-title":"Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/DAD.0000000000001418","article-title":"Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, with Mutations Distinct from V600E\/V600K","volume":"41","author":"Fernandes","year":"2019","journal-title":"Am. J. Dermatopathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4149\/neo_2017_419","article-title":"BRAF Inhibitors: Efficacious and Tolerable in BRAF-Mutant Acral and Mucosal Melanoma","volume":"64","author":"Bai","year":"2017","journal-title":"Neoplasma"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2020.12.021","article-title":"Outcome of Combination Therapy Using BRAF and MEK Inhibitors among Asian Patients with Advanced Melanoma: An Analysis of 112 Cases","volume":"145","author":"Fujisawa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.tranon.2016.09.004","article-title":"Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma","volume":"9","author":"Kim","year":"2016","journal-title":"Transl. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Mao, L., Ding, Y., Bai, X., Sheng, X., Dai, J., Chi, Z., Cui, C., Kong, Y., Fan, Y., and Xu, Y. (2021). Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral\/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.720044"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s11864-022-01007-6","article-title":"Advanced Acral Melanoma Therapies: Current Status and Future Directions","volume":"23","author":"Zhang","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Kaszubski, J., Gagat, M., Grzanka, A., Wawrzyniak, A., Nikli\u0144ska, W., \u0141apot, M., and \u017bury\u0144, A. (2024). Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy. Molecules, 29.","DOI":"10.3390\/molecules29225239"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent Progress of CDK4\/6 Inhibitors\u2019 Current Practice in Breast Cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 Inhibition Triggers Anti-Tumor Immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejca.2021.02.021","article-title":"Palbociclib in Advanced Acral Melanoma with Genetic Aberrations in the Cyclin-Dependent Kinase 4 Pathway","volume":"148","author":"Mao","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41388-023-02900-6","article-title":"ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4\/6 Inhibitor Resistance in Acral Lentiginous Melanoma","volume":"43","author":"Jagirdar","year":"2024","journal-title":"Oncogene"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/1\/120\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:28:21Z","timestamp":1759919301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/1\/120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":134,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["biom15010120"],"URL":"https:\/\/doi.org\/10.3390\/biom15010120","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}